Drug Manufacturer Payments in Nursing Homes: When the Medication Review Becomes a Sales Call

Nursing home drug manufacturer pharmacy kickbacks buy influence over which drugs residents receive. The cases describe rebates paid to pharmacies, promotional material presented as clinical guidance, and physicians paid to speak to empty rooms. A manufacturer’s payment can reach the resident through a consultant pharmacist’s recommendation or a prescriber’s order, with Medicare or Medicaid paying for the drug. If you know how a rebate contract, medication review or speaker program worked inside the business, you may know why those prescriptions changed.

How Consultant Pharmacists Become a Manufacturer’s Sales Channel

In the Depakote cases, drug manufacturer payments allegedly reached nursing home prescribing through the consultant pharmacist. The government alleged that PharMerica received rebates, educational grants and financial support to recommend Abbott Laboratories’ drug. Required monthly medication reviews gave consultant pharmacists repeated opportunities to recommend changes to physicians.

That relationship puts a commercial agreement behind a clinical recommendation. A pharmacy employee or manufacturer sales representative may also know the contract that helped produce it.

For a covered Medicare Part A skilled nursing stay, the facility’s payment generally includes drugs, and the facility pays its pharmacy supplier. CMS’s consolidated-billing framework puts that expense inside the facility’s bill. In the clozapine case below, the government instead identified prescription claims paid by Medicare Part D and Illinois Medicaid. Manufacturer payments influence which drug gets prescribed upstream of those bills.

Depakote Pharmacy Rebates and Consultant Pharmacists

The Depakote nursing home case alleged that pharmacy rebates and consultant pharmacists helped carry Abbott’s off-label marketing into resident care. The whistleblower complaint describes pharmacy recommendations, prescription switches and treatment guides designed to promote the drug for agitation and aggression associated with dementia.

The guides borrowed the pharmacies’ identity:

The complaint alleges that the guides’ treatment algorithms placed Depakote first for dementia patients, an unapproved use. It also describes company-funded continuing education that used actors playing nursing home residents. A video ended with an actor’s agitation and aggression apparently controlled after the presentation promoted Depakote. The apparent clinical improvement was a performance.

This was promotion delivered through material a clinician might encounter as education or pharmacy guidance. The complaint separately alleges that PharMerica directed consultant pharmacists to recommend new prescriptions or switches after entering manufacturer contracts.

The pharmacies reached their own settlements. PharMerica agreed to pay $9.25 million in 2015. Omnicare agreed to pay $28.125 million in 2016 over alleged Abbott payments that included grants, educational funding and rebates linked to drug use. Former Abbott employees brought the whistleblower cases. Their knowledge reached beyond their employer to the pharmacies receiving its money.

Aranesp Interchange and Nursing Home Pharmacy Kickback Settlements

Aranesp interchange linked pharmacy rebates to efforts to move nursing home patients from a competing anemia drug. Amgen agreed to pay $24.9 million in 2013 to resolve allegations that it paid Omnicare, PharMerica and Kindred Healthcare to implement those switches for Medicare and Medicaid beneficiaries. The government said the rebates depended on market share or purchase volume.

The whistleblower complaint gives a contract example in which Omnicare’s rebate rose from 3% to 23% at a higher quarterly purchase threshold. It alleges that the financial incentives reached the medication review, physician solicitations and employee bonuses. A pharmacy call center contacted physicians by telephone and letter to encourage switches from Procrit to Aranesp. Regional scorecards tracked interchange results and helped determine bonuses.

The complaint describes how that looked from the nursing home:

The complaint also alleges that Amgen ran a contest rewarding sales employees for bringing nursing home beds under company-developed or company-influenced anemia protocols. The commercial target was a facility’s capacity to generate prescriptions. Monthly drug reviews then supplied repeated opportunities to seek the switch.

Omnicare’s separate $4.19 million settlement in 2014 concerned allegedly receiving rebates, grants, speaker and consulting payments, data fees, meals and travel tied to Aranesp switching. Both the manufacturer paying for influence and the pharmacy receiving the benefits faced civil claims.

Nuedexta in Nursing Homes: Separate Manufacturer and Physician Cases

Avanir Pharmaceuticals reached a civil settlement in 2019 over alleged inducements to prescribe Nuedexta and nursing home marketing for dementia-related behaviors.

In a separate 2022 complaint against an Alabama psychiatrist, the government alleged that manufacturer speaker payments rewarded prescribing. It described programs with few attendees and little value. The complaint went further:

The alleged referral arrangement was equally concrete. The practice manager sent the physician’s monthly schedule to company salespeople. They could visit the nursing homes ahead of him and persuade staff to refer residents to his practice. The complaint alleges that those valuable referrals were exchanged for Nuedexta prescriptions.

The government also challenged the medical basis for the prescriptions. Nuedexta’s approved use was pseudobulbar affect, characterized by involuntary laughing or crying. The complaint described a resident who lacked that condition or its symptoms but whose drug was billed to Medicare Part D. It alleged that Medicare paid more than $6 million for Nuedexta prescriptions for the psychiatrist’s patients from 2015 through 2019.

The alleged bargain left residents taking drugs they did not need and taxpayers paying for them.

Clozapine Consulting Payments and Prescribing

The clozapine cases put a consulting agreement beside a physician’s decision to switch patients’ medication. Teva Pharmaceuticals USA and IVAX agreed to pay more than $27.6 million in 2014 to resolve allegations that payments induced generic clozapine prescriptions for Medicare and Medicaid patients in nursing homes and hospitals around Chicago.

The government alleged that the psychiatrist proposed switching patients if IVAX paid him $50,000 under a consulting agreement and provided other benefits. The alleged benefits included travel, meals, entertainment and sporting-event tickets. The resulting claims went to Medicare Part D and Illinois Medicaid.

The physician later agreed to a separate $3.79 million civil settlement in 2015. The allegations concerned prescriptions and medication-management claims for patients in nursing homes and other facilities.

Janssen, Omnicare and the Size of the Nursing Home Component

Johnson & Johnson and Janssen’s Omnicare settlement identified a specific nursing home pharmacy component within a much broader drug resolution. The companies agreed to pay $149 million in 2013 to resolve allegations that payments to Omnicare caused false claims to federal health care programs.

The government alleged that market-share rebates, data-purchase agreements, grants and educational funding bought consultant-pharmacist promotion of Risperdal and other Johnson & Johnson drugs. Those pharmacists reviewed residents’ charts and recommended drugs to physicians. The alleged arrangement turned that trusted position into a manufacturer sales channel.

Omnicare had already agreed to its own $98 million civil settlement in 2009 covering the alleged acceptance of those payments and other conduct.

Abbott’s $800 million civil Depakote settlement in 2012 likewise covered a wider set of uses and government programs. The nursing home pharmacy allegations were part of that larger resolution.

What Evidence Is Needed to Prove Fraud?

The case depends on connecting the payment to the prescription and the government-paid claim. Our whistleblower experts help you show that connection, drawing on what you know about the commercial arrangement and the prescribing it influenced.

The California Research Bureau’s 1997 report, Fraud and Abuse in the Health Care Market of California, describes how paid steering can operate at different levels of the healthcare market. These drug cases show why that matters: the prescription can be real while a payment behind its selection drives the alleged fraud.

In the Depakote allegations, promotional guides connect manufacturer messaging to pharmacy recommendations. In Aranesp, contracts, interchange scorecards and drug reviews connect the rebate to the switch. In the Nuedexta complaint, company attendance records sit beside speaker fees, patient referrals and Medicare claims. Someone who worked with one of those records may be able to explain a connection that a claims spreadsheet cannot show by itself.

What Is the Reward for a Medicare Fraud Whistleblower?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. A former Abbott employee received a $1 million whistleblower reward from the federal share of PharMerica’s Depakote settlement. A manufacturer’s employee exposed a payment arrangement involving the pharmacy it paid. Knowledge of the commercial relationship can be central to a case even when another business submitted the drug claim.

Who Paid for the Recommendation?

If you know the rebate deal behind a drug switch or the real purpose of a speaker payment, talk with our whistleblower experts about the arrangement. We build the case strategy around that inside knowledge and bring in pharmaceutical fraud whistleblower lawyers who understand manufacturer payments and nursing home prescribing. We stay beside you through the case, connecting the commercial decisions you saw to the government payments they produced.